CeNeRx BioPharma Initiates Phase II Clinical Trial Of Its Novel Antidepressant Agent Tyrima(TM)

Posted by on October 29th, 2008 at 05:00am

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, announced that it has initiated a Phase II clinical trial for its lead product candidate Tyrima(TM) for the treatment of major depressive disorder (MDD). Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A (MAO-A).

Spread the Love & Syndicate
  • del.icio.us
  • YahooMyWeb
  • digg
  • Furl
  • description
  • De.lirio.us
  • co.mments
  • Ma.gnolia
  • Reddit
  • Spurl
  • Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression
  • National Positive Thinking Trial Aims To Prevent Childhood Depression
  • AMPAKINE Compound, CX717, Achieves Primary Endpoints In Second Phase IIa Respiratory Depression Study In Germany
  • How To Ease Panic And Anxiety Attacks

    • Under Depression

    Leave a Comment for CeNeRx BioPharma Initiates Phase II Clinical Trial Of Its Novel Antidepressant Agent Tyrima(TM)

    Required

    Required, hidden

    Trackback this post  |  Subscribe to the comments via RSS Feed

    Recent Blog Posts

    Categories

    Posts by Month

    Resources